Indefinite Delivery Contract HHSN272201600009I

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded Sri International a multiple award indefinite delivery contract to provide resources advancing pediatrics and HIV prevention science. Valued at up to $98.8 million over seven years, the contract aims to support preclinical gap filling, animal model studies, bioanalytical services, product manufacturing, and scientific/quality assistance. Sri International has also received a $45,041 delivery order...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract valued at up to $98,878,757 to multiple vendors under the Resources to Advance Pediatrics and HIV Prevention Science master contract. Tulane University received a $21,632 delivery order as the prime contractor to support the goals of the master contract in New Orleans, Louisiana from April 2023 through June 2024 on a cost-no-fee basis. The originating pre-solicitation...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded an indefinite delivery/indefinite quantity contract valued at $98.9 million to Lovelace Biomedical Research Institute under the Resources to Advance Pediatrics and HIV Prevention Science master contract. The contract aims to procure preclinical development support services for HIV, pediatric, and prevention products through April 2030. Services include preclinical gap filling, animal model studies,...

This Indefinite Delivery Contract (IDC) was awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Southern Research Institute, a non-profit organization. The contract, valued at up to $24,293,824, is for an "In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides" and does not have a set-aside designation. Under this IDC, Southern Research Institute is providing a range of services, including optimization and...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. Valued at up to $107 million over seven years, the contracts authorize task orders across seven areas including in vitro testing, synthesis of therapeutic agents, small animal models, formulation development,...

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, has awarded a $107,274,471 Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Southern Research Institute, a non-profit research organization, to provide preclinical development support for candidate products and drug development activities related to HIV therapeutics. The contract does not have a set-aside designation and has a period of...

Advanced Bioscience Laboratories, Inc. (ABL) has been awarded a multiple-award Indefinite Delivery Vehicle (IDV) valued at $98.9 million by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the National Institutes of Health, to provide comprehensive preclinical development support services under the "Resources to Advance Pediatrics and HIV Prevention Science" program. The IDV, which carries no set-aside designation and is scheduled for...

The National Institutes of Health's National Institute of Child Health and Human Development awarded an indefinite delivery contract to The Regents of the University of California, San Francisco to conduct clinical trials in support of contraceptive development. With a potential value of $5 million and a period of performance through July 2027, this multiple-award contract enables the agency to issue task orders for phase I-IV contraceptive trials in women and treatment trials for gynecologic...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Services will be conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for...

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract worth up to $107,274,471 to provide preclinical development support for candidate products and drug development activities related to HIV, hepatitis B and C, and tuberculosis. This multiple-award IDIQ contract has a 7-year period of performance from October 2020 to October 2027. The scope...